Nordic Luveris Study
Phase 4
Completed
- Conditions
- InfertilityIn Vitro Fertilization
- Interventions
- Drug: recombinant follicle stimulating hormone (Gonal-f)Drug: recombinant luteinizing hormone (Luveris)
- Registration Number
- NCT00553293
- Lead Sponsor
- Rigshospitalet, Denmark
- Brief Summary
To study whether addition of human LH hormone (Luveris) during the final days of stimulation with recombinant FSH (Gonal-f) for controlled ovarian stimulation will be of benefit for patients undergoing in vitro fertilisation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 526
Inclusion Criteria
- Age below 40
- Infertility treatable by IVF or ICSI
- Regular cycles
Exclusion Criteria
- NA
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description A,2 recombinant follicle stimulating hormone (Gonal-f) rFSH alone A,1 recombinant luteinizing hormone (Luveris) rFSH + rLH arm
- Primary Outcome Measures
Name Time Method Ongoing pregnancy rate per started stimulation cycle ultrasound showing ongoing pregnancy
- Secondary Outcome Measures
Name Time Method Ongoing pregnancy in subgroups of patients with lo0w serum LH levels ultrasound for ongoing pregnancy in subgroups
Trial Locations
- Locations (1)
Anders Nyboe Andersen
🇩🇰Copenhagen, Denmark